Oncternal Therapeutics Inc (NAS:ONCT)
$ 0.5266 0 (0%) Market Cap: 1.56 Mil Enterprise Value: -12.83 Mil PE Ratio: 0 PB Ratio: 0.17 GF Score: 29/100

Oncternal Therapeutics Inc Key Opinion Leader (KOL) Webinar on Cirmtuzumab for Treating Patients with Mantle Cell Transcript

Jul 29, 2020 / 05:30PM GMT
Release Date Price: $65.6 (+5.81%)
Operator

Good afternoon, and welcome to the Oncternal Therapeutics KOL Call on Cirmtuzumab for the Treatment of Mantle Cell Lymphoma. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Oncternal website following the event.

I would now like to turn the call over to your host, Dr. James Breitmeyer, Chief Executive Officer at Oncternal Therapeutics. Please go ahead, Doctor.

James B. Breitmeyer
Oncternal Therapeutics, Inc. - President, CEO & Director

Thank you, Sarah, and welcome, everybody. Thanks for joining us on this call to discuss the current therapeutic landscape for mantle cell lymphoma and the role that Oncternal's drug cirmtuzumab may play as a potential new treatment in that disease. The primary goal of this call is for you to hear from Dr. Michael Wang, a true key opinion leader in the field of hematology, and more specifically, in mantle cell lymphoma.

Next slide, please. As you can see from this agenda, after my opening remarks, I'll turn it over to Dr. Wang to discuss

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot